This article is more than 5 years old. Information may no longer be current.
Wize's LO2A shows positive results in Sjögren's-related dry eye
Click Here to Manage Email Alerts
A study found LO2A resulted in a significant improvement of both subjective and objective symptoms of Sjögren’s syndrome-related dry eye disease, Wize Pharma announced in a press release.
The 21-patient prospective, unmasked study found LO2A significantly decreased the lid parallel conjunctival folds degree from 2.48 ± 0.75 on the right eye and 2.57 ± 0.75 on the left eye to 1.33 ± 0.73 and 1.38 ± 0.67, respectively, after 3 months, according to data presented in a poster at the Association for Research in Vision and Ophthalmology meeting. Initial lissamine green staining of the eye surface also decreased significantly from 1.76 ± 0.89 to 0.29 ± 0.56 for the right eye and from 1.95 ± 0.86 to 0.29 ± 0.56 for the left eye.
Ocular surface disease index values decreased significantly, while there were no significant changes in tear secretion.
“This data supports our development efforts for LO2A in multiple markets including Israel where we are currently enrolling patients in a randomized, double-masked phase 4 study in this indication,” Wize Chairman Ron Mayron said in the release.